Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new study finds that only 23% of preterm patients given magnesium sulfate for fetal neuroprotection delivered within 24 hours of the first dose — with a median time to delivery of nearly 8 days. The findings highlight a significant mismatch between clinical expectations and real-world outcomes, helping explain why repeat dosing during prolonged hospitalizations is so common.
Magnesium sulfate is routinely given to pregnant patients at risk of imminent preterm delivery to protect the baby's developing brain — but a new multicenter study suggests the timing assumptions behind this protocol may be off. Researchers analyzed 692 patients who received magnesium sulfate for fetal neuroprotection between 23 and 31 weeks' gestation across seven U.S. hospitals, finding that only 23% delivered within 24 hours of the initial dose, with a median latency of nearly 8 days.
When repeat administrations during the same hospitalization were factored in, more than half (53.6%) delivered within 24 hours of some treatment course — meaning repeat dosing is both common and clinically meaningful. Clinical indication also mattered: patients with preterm labor and intact membranes or vaginal bleeding were more likely to be discharged home undelivered.
By the Numbers:
Why it matters: These findings challenge the assumption that magnesium sulfate administration signals imminent delivery, and provide data-driven context for why repeat dosing is so prevalent. For clinicians managing preterm pregnancies, this underscores the need to reassess protocols and set more realistic expectations around delivery timing.
